HSBC Holdings
SRPT icon

HSBC Holdings’s Sarepta Therapeutics SRPT Stock Holding History

HSBC Holdings’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$12.1M – 3245
2024
Q4 		$12.1M Buy
+100,000
New +$12.3M 0.01% 871

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HSBC Holdings's SRPT Position: Q1 2026 in Review

HSBC Holdings increased its Sarepta Therapeutics (SRPT) stake by 66% in Q1 2026, buying an estimated $426K and bringing the position to 55,549 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

HSBC Holdings first reported a position in SRPT in Q4 2016 and has held it in 28 quarters since. The position peaked at $21.9M in Q4 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • HSBC Holdings held 55,549 shares of Sarepta Therapeutics worth $1.22M as of Q1 2026.
  • HSBC Holdings bought 22,001 Sarepta Therapeutics shares in Q1 2026, an estimated $426K.
  • Sarepta Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1762 holding.
  • HSBC Holdings first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 28 quarters since.
  • HSBC Holdings's Sarepta Therapeutics position peaked at $21.9M in Q4 2024.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.